RMC No. 124-2022 updates VAT-exempt medicines under CREATE for cancer, tuberculosis, mental illness, diabetes, and hypertension based on FDA publication.
Businesses selling, importing, prescribing, dispensing, accounting for, or claiming VAT treatment on covered medicines must check the updated VAT-exempt medicine list immediately because the exemption applies based on the date the Food and Drug Administration publishes the updates. RMC No. 124-2022 matters to pharmacies, hospitals, clinics, distributors, importers, accountants, and finance teams because it updates the medicines that may be treated as VAT-exempt under Republic Act No. 11534, otherwise known as the CREATE Act.
What RMC No. 124-2022 Changed
RMC No. 124-2022, issued on September 1, 2022, publishes the August 15, 2022 letter from Food and Drug Administration Director General Samuel A. Zacate endorsing updates to the List of VAT-Exempt Medicines under the CREATE Act. The update affects medicines prescribed for cancer, tuberculosis, and mental illness, and also corrects medicines prescribed for diabetes and hypertension.
The practical effect is that the VAT treatment of the covered medicines must be aligned with the updated FDA list. For businesses, this is not merely a product-labeling matter. It affects pricing, invoicing, VAT reporting, accounting systems, point-of-sale treatment, supplier documentation, and tax compliance review. A medicine that is included in the updated list may be treated as VAT-exempt from the applicable effectivity date, while medicines that are not within the updated list should not automatically be treated as VAT-exempt merely because they relate generally to a disease category.
Key Rule: FDA Publication Controls the Effectivity of the VAT Exemption
The most important compliance rule in RMC No. 124-2022 is its reminder of the clarification under Q&A No. 1 of Revenue Memorandum Circular No. 99-2021. The VAT exemption of the covered medicines and medical devices under the CREATE Act takes effect on the date of publication by the FDA of the updates to the List of VAT-Exempt Medicines.
This means that tax teams should not rely solely on the date of the BIR circular, the date of the FDA letter, or the date a supplier informs the company of a product classification. The controlling date identified in the circular is the FDA publication date of the update to the list. For accounting and invoicing purposes, this matters because a business may need to determine whether a particular sale occurred before or after the relevant FDA publication date.
Common search phrases for this issue include VAT exempt medicines Philippines, CREATE Act VAT exemption medicines, FDA VAT exempt medicine list, RMC 124-2022 VAT medicines, VAT exemption cancer tuberculosis mental illness medicines, and diabetes hypertension VAT exempt medicines. These are the phrases finance teams and tax managers are likely to use when checking whether medicines should be sold or recorded as VAT-exempt.
Who Is Most Affected
The businesses most affected are pharmacies, drugstores, hospitals, clinics, pharmaceutical distributors, importers, wholesalers, medical procurement groups, health maintenance organizations, and companies that buy medicines in bulk for employees, patients, or institutional use. The circular is also relevant to CFOs, corporate accountants, tax managers, and in-house counsel who review VAT classification, billing, and compliance controls.
Pharmaceutical suppliers and retailers should be especially careful because the list now includes medicines prescribed for cancer, tuberculosis, and mental illness, while also correcting medicines prescribed for diabetes and hypertension. A correction to an existing category is important because it may require product master files, POS systems, ERP tax codes, price displays, and invoice templates to be reviewed against the updated FDA list.
Hospitals and clinics should also review their billing systems. In practice, medicines may be billed together with other goods or services. If the medicine component is VAT-exempt under the updated list, the billing team should ensure that the VAT treatment is correctly applied and properly supported. Otherwise, the business may end up charging VAT on an exempt medicine or treating a non-covered item as exempt.
Covered Disease Categories in the Update
RMC No. 124-2022 identifies the updated list as covering medicines prescribed for cancer, tuberculosis, and mental illness. It also states that the update corrects medicines prescribed for diabetes and hypertension. These categories should be reviewed with precision. The circular does not say that every medicine connected in any way with these conditions is automatically exempt. The operative reference remains the updated List of VAT-Exempt Medicines endorsed through the FDA update.
For finance teams, the correct approach is product-specific verification. The accounting treatment should be based on whether the medicine is in the updated FDA list, not merely on internal product descriptions, supplier marketing materials, or a broad disease category. Businesses should keep a record of the FDA list relied upon, the publication date used for effectivity, and the internal approval or review that caused the product to be mapped as VAT-exempt.
Compliance Requirements and Deadlines
RMC No. 124-2022 was issued on September 1, 2022. The FDA letter referenced in the circular is dated August 15, 2022. However, the operative timing rule emphasized by the circular is that the VAT exemption takes effect on the date of publication by the FDA of the updates to the List of VAT-Exempt Medicines.
Businesses should therefore identify the FDA publication date for the relevant update and use that date as the cut-off for VAT treatment. Sales before the applicable FDA publication date should be reviewed separately from sales on or after the publication date. This is particularly important where a company changed its VAT coding only after receiving supplier notice, after internal tax review, or after the BIR circular date. Internal cut-off errors may affect VAT returns, invoices, official receipts, credit memos, and customer claims.
The circular does not prescribe a separate filing deadline for taxpayers to apply the update. It also does not impose a special registration procedure in the text summarized here. The immediate compliance action is operational: check the updated FDA list, confirm the effectivity date based on FDA publication, update tax coding, and ensure that invoicing and VAT reporting follow the correct classification.
Penalties and Risks for Non-Compliance
RMC No. 124-2022 does not state a special penalty for failure to apply the updated List of VAT-Exempt Medicines. However, the absence of a special penalty does not make the issue low-risk. VAT classification affects tax returns, invoices, pricing, and customer charges. A business that treats a product as VAT-exempt without support from the updated list may face tax exposure during audit. A business that charges VAT on a medicine that should be VAT-exempt may face commercial, accounting, and customer-relations issues, especially for institutional buyers and healthcare purchasers.
For CFOs and accountants, the risk is often not a single transaction but repeated miscoding. If a product master file or POS system applies the wrong VAT code, the error may recur across multiple branches, invoices, and reporting periods. This is why RMC No. 124-2022 should be treated as a trigger for a product-level VAT review, not just a circular to be filed for reference.
Practical Steps for Businesses
First, obtain and review the updated FDA List of VAT-Exempt Medicines referred to in RMC No. 124-2022. Confirm which specific medicines are included for cancer, tuberculosis, and mental illness, and which diabetes and hypertension medicines were corrected. Second, identify the FDA publication date of the update because that is the date from which the VAT exemption takes effect under the clarification cited from RMC No. 99-2021.
Third, update the company product master list, ERP system, point-of-sale system, and invoicing templates so the correct VAT treatment is applied. Fourth, document the basis for the VAT-exempt classification, including the circular reference, FDA update, publication date, and internal tax review. Fifth, review transactions around the effectivity date to confirm that sales were coded correctly before and after the FDA publication date.
Sixth, coordinate between tax, finance, sales, procurement, and legal teams. VAT treatment of medicines often crosses departments: procurement receives supplier documents, pharmacy or operations teams manage product codes, finance prepares VAT returns, and legal or compliance teams handle audit support. RMC No. 124-2022 requires these teams to work from the same updated list and the same effectivity date.
How Ablola, Saribong & Gueco Can Help
Ablola, Saribong & Gueco assists businesses, pharmacies, healthcare providers, importers, distributors, and corporate finance teams in reviewing BIR issuances, VAT-exempt classifications, tax documentation, and audit-readiness controls. For RMC No. 124-2022, the key task is to align the companyβs invoicing and VAT reporting with the updated FDA List of VAT-Exempt Medicines and the FDA publication-based effectivity rule.
If your business sells, imports, distributes, prescribes, or accounts for medicines affected by the CREATE Act VAT exemption, ASG Law can help review your VAT treatment, prepare internal compliance guidance, and support your team in handling BIR audit questions. For legal and tax assistance on RMC No. 124-2022, VAT-exempt medicines, and BIR compliance in the Philippines, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.